From The Corner Lab - Blog Posts

Jim Menoutis

Recent Posts

FDA Publishes Q&A on Draft Guidance - ANDAs: Stability Testing of Drug Substances and Products

Posted by Jim Menoutis on Mon, Sep 09, 2013 @ 10:15 AM

FDA published its long awaited draft guidance for industry, ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers, in the Federal Register August. 27, 2013. The document provides answers to questions submitted during the public comment period on the draft stability guidance that was published on September 25, 2012. The final guidance for industry was published on June 20, 2013. The question-and-answer draft guidance document is open for comment for the next 60 days.

Read More

Topics: DMF, Drug Master File, Drug Substance, Drug Product, Generic Drug, ICH Stability Guidlines, FDA ANDA Guidance, CDER, OGD, Office of Generic Drugs, Stability Testing

ICH Issues Q3D step 2b Elemental Impurities Guideline; USP & EMA Take Action

Posted by Jim Menoutis on Wed, Aug 28, 2013 @ 05:17 PM

The International Conference on Harmonization (ICH) has started the consultation period on elemental impurities. ICH Q3D - Impurities: Guideline for Elemental Impurities - laying out limits for metallic impurities in pharmaceutical ingredients and preparations and detailing the testing procedures used to detect and measure them.  With the July 26, 2013 issuance of the guideline, Q3D has now entered step 2b of a five-step implementation process. There is a six-month comment period which gives  the industry and other stakeholders time to forward their comments.

Read More

Topics: Elemental Impurities, CHMP, USP <232>, USP <233> elemental Impurities, FDA, ICH, Q3D, EMA

FDA Adopts ICH Standards for Generics Stability Testing Involving ANDAs

Posted by Jim Menoutis on Mon, Jul 08, 2013 @ 03:55 PM

The US Food and Drug Administration (FDA) has released a new  2 page guidance for industry that pertains to stability  testing recommendations for generic drug products submitted under 505(j) of the Federal Food, Drug and Cosmetic Act (FD&C Act) as an abbreviated new drug application (ANDA) or a drug master file (DMF).

Read More

Topics: Generic Drug, ICH Stability Guidlines, FDA ANDA Guidance, CDER, OGD, Office of Generic Drugs

Virginia Law Is Nation’s First Dealing With Substitution of Biosimilars

Posted by Jim Menoutis on Fri, Apr 05, 2013 @ 11:32 AM

A new Virginia law is the first in the country that would prevent the automatic substitution of non-interchangeable biosimilars. Pharmacists substituting an interchangeable biosimilar for a brand product would need to inform the patient prior to the switch. Amgen and Genentech have been pushing state legislators to enact measures, including Virginia’s H.B. 1422, but the generic industry says such rules will create hurdles for the uptake of biosimilars.

Read More

Topics: biologic drug generic drug, branded drug, Biosimilars

Quantex Announces Move To Larger Facility, Former Headquarters of Pharmacopeia Drug Discovery

Posted by Jim Menoutis on Fri, Feb 22, 2013 @ 10:55 AM

Quantex Laboratories has completed the expansion of its GMP analytical laboratory with its relocation to a larger, state of the art facility at 3000 Eastpark Boulevard in Cranbury, New Jersey. With the new facility nearly four times the size of Quantex Laboratories’ previous site, the company is also adding microbiological testing capabilities later in the year to its contract laboratory and analytical testing CRO services. 

Read More

Topics: cGMP, Analytical Outsourcing, Pharmacopeia, Drug Development, CRO, Release Testing, Pharmaceutical Outsourcing

Indian Government Moves to Ban Medicines From Being Sold Under Branded Names

Posted by Jim Menoutis on Fri, Oct 19, 2012 @ 04:39 PM

The Drug controller general  of India has moved to  prohibit medicines from being sold under brand names. As a result, earlier this week, states were ordered to stop issuing licenses for the manufacture or sale of drugs under brand names This move is already raising objections from domestic drug makers. The effort is designed to accelerate the sale of lower-cost generics in India.

Read More

Topics: Generics, Indian Pharmaceuticals, Non-branded drugs, Indian Generics, India Trademarks

Heparin Supply May Be Impacted By Global Pork Shortage

Posted by Jim Menoutis on Wed, Oct 17, 2012 @ 04:43 PM

According to recent reports an anticipated decline in the global pig population may result is heparin shortages next year.  The decline is due in no small part to the increasing costs for feed and other animal welfare costs to farmers. In the US, the on-going drought in the farm belt has had a significant impact. In response, President Barack Obama introduced a pork buying program to support the industry. A comparable plan has also been implemented in China.

Read More

Topics: Heparin, heparin supply, adulterated heparin, heparin shortage

Major Cancer Center Say No To New Cancer Med. Rationale Or Rationing?

Posted by Jim Menoutis on Mon, Oct 15, 2012 @ 03:43 PM

With all the talk of rising prices for cancer medications, the cost of healthcare and comparing the value and benefit of competing drugs, Memorial Sloan-Kettering Cancer Center has decided not to use a newly approved treatment for metastatic colorectal cancer. The leading hospital says it will exclude the new colorectal cancer drug Zaltrap which is marketed by Sanofi and Regeneron, from its treatment protocol.  

Read More

Topics: Roche, Zaltrop, treatment protocol, Sanofi, Cancer Treatment, Avastin, Regeneron, medical rationing, healthcare rationing

Merck To Relocate Its Headquarters

Posted by Jim Menoutis on Wed, Oct 10, 2012 @ 01:18 PM

Since 1992, Merck has called  Whitehouse Station, NJ home to its corporate headquarters. Now followings its merger with Schering Plough in 2009, it has decided to close and shutter the facility, relocating its headquarters and some  2,00 employees and contractors to new digs scattered around New Jersey. And the company is billing the move as a sign of its increasing corporate.

Read More

Topics: Roche, USP, Generic Version, Merck, Merck R&D, Merck Whitehouse Station, Generics, Life science research, Merck to Move, Sanofi

Medical Technology Set To Out Pace Pharma Industry

Posted by Jim Menoutis on Mon, Oct 08, 2012 @ 12:43 PM

The medical technology (medtech) market is forecasted to grow at 4.4 percent per year between 2011 and 2018, to reach $440 billion, according to a new report from EvaluatePharma, the EvaluateMedTech World Preview 2018. This growth will outpace the global pharmaceutical Industry, which has long over shadowed the medtech sector. This report finds that  medtech is expected to grow 2.5 percent per year between 2011 and 2018.

Read More

Topics: Johnson & Johnson, Roche, Medtronic, in-vitro diagnostics sector, orthopedics sector, top medical device sectors, medical technology (medtech) market is forecasted, to reach $440 billion